HRP990074A2 - Compound and its use - Google Patents
Compound and its use Download PDFInfo
- Publication number
- HRP990074A2 HRP990074A2 HR990074A HRP990074A HRP990074A2 HR P990074 A2 HRP990074 A2 HR P990074A2 HR 990074 A HR990074 A HR 990074A HR P990074 A HRP990074 A HR P990074A HR P990074 A2 HRP990074 A2 HR P990074A2
- Authority
- HR
- Croatia
- Prior art keywords
- sample
- solution
- lamotrigine
- compound
- dichlorophenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 57
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 81
- 229960001848 lamotrigine Drugs 0.000 claims description 80
- 239000000243 solution Substances 0.000 claims description 57
- 239000000523 sample Substances 0.000 claims description 37
- 239000012086 standard solution Substances 0.000 claims description 31
- 239000012488 sample solution Substances 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 22
- 238000004809 thin layer chromatography Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 17
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- OVNGWOHWYFBGKF-UHFFFAOYSA-N 3-amino-6-(2,3-dichlorophenyl)-2h-1,2,4-triazin-5-one Chemical compound OC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl OVNGWOHWYFBGKF-UHFFFAOYSA-N 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 11
- 238000006731 degradation reaction Methods 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- RDUGDEWOUWFKPL-UHFFFAOYSA-N n-[5-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-3-yl]-2,3-dichlorobenzamide Chemical compound N=1N=C(C=2C(=C(Cl)C=CC=2)Cl)C(N)=NC=1NC(=O)C1=CC=CC(Cl)=C1Cl RDUGDEWOUWFKPL-UHFFFAOYSA-N 0.000 claims description 7
- FIBBFBXFASKAON-UHFFFAOYSA-N 2,3-dichlorobenzoyl cyanide Chemical compound ClC1=CC=CC(C(=O)C#N)=C1Cl FIBBFBXFASKAON-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- OTXHZHQQWQTQMW-UHFFFAOYSA-N (diaminomethylideneamino)azanium;hydrogen carbonate Chemical compound OC([O-])=O.N[NH2+]C(N)=N OTXHZHQQWQTQMW-UHFFFAOYSA-N 0.000 claims description 4
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 229940126062 Compound A Drugs 0.000 description 21
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 239000000356 contaminant Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012490 blank solution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- BXDSJOGMJUKSAE-CHHVJCJISA-N (1e)-2,3-dichloro-n-(diaminomethylideneamino)benzenecarboximidoyl cyanide Chemical compound NC(N)=N\N=C(\C#N)C1=CC=CC(Cl)=C1Cl BXDSJOGMJUKSAE-CHHVJCJISA-N 0.000 description 1
- GKNCZOMKFQSLCL-WYMPLXKRSA-N (1z)-2,3-dichloro-n-[[n'-(2,3-dichlorobenzoyl)carbamimidoyl]amino]benzenecarboximidoyl cyanide Chemical compound C=1C=CC(Cl)=C(Cl)C=1C(=O)N=C(N)N\N=C(/C#N)C1=CC=CC(Cl)=C1Cl GKNCZOMKFQSLCL-WYMPLXKRSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9812413.4A GB9812413D0 (en) | 1998-06-10 | 1998-06-10 | Compound and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP990074A2 true HRP990074A2 (en) | 2000-10-31 |
Family
ID=10833464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR990074A HRP990074A2 (en) | 1998-06-10 | 1999-03-09 | Compound and its use |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6333198B1 (de) |
| EP (2) | EP1170588A1 (de) |
| JP (1) | JP2989189B1 (de) |
| KR (1) | KR100322354B1 (de) |
| CN (2) | CN1238454A (de) |
| AP (3) | AP9901481A0 (de) |
| AR (1) | AR014074A1 (de) |
| AT (1) | ATE218552T1 (de) |
| AU (1) | AU2031999A (de) |
| BR (1) | BR9900984A (de) |
| CA (1) | CA2265194C (de) |
| DE (1) | DE69901656T2 (de) |
| DK (1) | DK0963980T3 (de) |
| EA (1) | EA000666B1 (de) |
| ES (1) | ES2178342T3 (de) |
| GB (1) | GB9812413D0 (de) |
| HR (1) | HRP990074A2 (de) |
| HU (1) | HUP9900592A3 (de) |
| ID (1) | ID22957A (de) |
| MA (1) | MA24777A1 (de) |
| NO (2) | NO991151L (de) |
| NZ (1) | NZ334590A (de) |
| PE (1) | PE20000332A1 (de) |
| PL (1) | PL331870A1 (de) |
| PT (1) | PT963980E (de) |
| SG (1) | SG85628A1 (de) |
| SI (1) | SI0963980T1 (de) |
| TR (1) | TR199900520A2 (de) |
| UY (1) | UY25946A1 (de) |
| YU (1) | YU12399A (de) |
| ZA (1) | ZA991951B (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020055177A1 (en) * | 1999-03-10 | 2002-05-09 | Glaxo Wellcome Inc. | Compound and its use |
| GB2372988B (en) * | 2000-01-03 | 2004-04-07 | Rpg Life Sciences Ltd | A process for the preparation of 6-(2,3-Dichlorophenyl)-1,2,4- Triazine-3,5-Diamine, commonly known as Lamotrigine |
| CA2433181C (en) | 2000-12-29 | 2005-11-22 | Pfizer Limited | Amlodipine hemifumarate |
| US6653481B2 (en) | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
| AT5874U1 (de) | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| CA2433284A1 (en) | 2000-12-29 | 2002-07-11 | Pfizer Limited | Reference standards and processes for determining the purity or stability of amlodipine maleate |
| EP1309558A1 (de) | 2000-12-29 | 2003-05-14 | Synthon Licensing, Ltd. | Aspartat-derivat von amlodipine als kalzium-kanal antagonist |
| WO2002053541A1 (en) | 2000-12-29 | 2002-07-11 | Pfizer Limited | Amide derivative of amlodipine |
| AP2003002820A0 (en) | 2000-12-29 | 2003-06-30 | Pfizer Ltd | "Process for making amlodipine maleate" |
| MXPA03005882A (es) | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado amida de amlodipina. |
| US7335380B2 (en) | 2000-12-29 | 2008-02-26 | Synthon Ip Inc. | Amlodipine free base |
| EP1309557B9 (de) | 2000-12-29 | 2006-11-15 | Pfizer Limited | Amlodipin-hemimaleat |
| DE10134980C2 (de) * | 2001-07-17 | 2003-05-28 | Helm Ag | Verfahren zur Herstellung von Lamotrigin |
| CA2366521C (en) | 2001-12-24 | 2007-03-06 | Brantford Chemicals Inc. | A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines |
| WO2003080065A1 (en) * | 2002-03-20 | 2003-10-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of quetiapine hemifumarate |
| HU225667B1 (en) | 2002-09-20 | 2007-05-29 | Richter Gedeon Nyrt | Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine |
| ES2209639B1 (es) | 2002-10-31 | 2005-08-01 | Vita Cientifica, S.L. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio. |
| GB2395483A (en) * | 2003-07-03 | 2004-05-26 | Jubilant Organosys Ltd | Crystalline lamotrigine and its monohydrate |
| CA2537271A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
| CA2546701C (en) * | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| WO2005056534A1 (en) * | 2003-12-02 | 2005-06-23 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| CA2554572A1 (en) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries Ltd. | Montelukast free acid polymorphs |
| WO2005075427A2 (en) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries Ltd. | Montelukast sodium polymorphs |
| MD2823G2 (ro) * | 2004-02-12 | 2006-05-31 | Институт Химии Академии Наук Молдовы | Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat |
| DE602005015174D1 (de) * | 2004-04-21 | 2009-08-13 | Teva Pharma | Verfahren zur herstellung von montelukast-natrium |
| TW200613294A (en) * | 2004-04-26 | 2006-05-01 | Teva Gyogyszergyar Reszvenytarsasag | Process for preparation of mycophenolic acid and ester derivatives thereof |
| US20050250773A1 (en) * | 2004-04-27 | 2005-11-10 | Sandor Molnar | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| WO2006004976A2 (en) * | 2004-06-28 | 2006-01-12 | Teva Pharmaceutical Fine Chemicals S.R.L. | Process for the preparation of atomoxetine hydrochloride |
| JP2007508379A (ja) * | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法 |
| WO2006012385A2 (en) * | 2004-07-20 | 2006-02-02 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg | Crystalline mycophenolate sodium |
| WO2006020348A2 (en) * | 2004-07-22 | 2006-02-23 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of atomoxetine hydrochloride |
| US7629461B2 (en) * | 2004-09-04 | 2009-12-08 | Teva Pharmaceutical Industries Ltd | Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| WO2006037125A1 (en) * | 2004-09-28 | 2006-04-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| WO2006045120A2 (en) * | 2004-10-19 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Purification of tegaserod maleate |
| US7678551B2 (en) * | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
| JP2007523213A (ja) * | 2004-12-23 | 2007-08-16 | テバ ファーマシューティカル インダストリーズ リミティド | 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法 |
| CA2591666A1 (en) * | 2005-01-11 | 2006-07-20 | Teva Pharmaceutical Fine Chemicals S.R.L. | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride |
| US20070037979A1 (en) * | 2005-02-22 | 2007-02-15 | Valerie Niddam-Hildesheim | Preparation of rosuvastatin |
| KR100945763B1 (ko) | 2005-02-22 | 2010-03-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 제조 방법 |
| US20070167625A1 (en) * | 2005-02-22 | 2007-07-19 | Anna Balanov | Preparation of rosuvastatin |
| CA2602073A1 (en) * | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of linezolid intermediate |
| EP1874754A1 (de) * | 2005-03-14 | 2008-01-09 | Teva Pharmaceutical Industries Ltd | Reines duloxetinhydrochlorid |
| MX2007010268A (es) * | 2005-04-05 | 2008-02-19 | Teva Pharm Fine Chemicals Srl | Clorhidrato de atomoxetina estable, un proceso para la preparacion del mismo, y un control analitico de su estabilidad. |
| WO2006108151A1 (en) * | 2005-04-06 | 2006-10-12 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of pregabalin |
| US7488846B2 (en) * | 2005-04-11 | 2009-02-10 | Teva Pharmaceuical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
| US20070066846A1 (en) * | 2005-04-11 | 2007-03-22 | Asher Maymon | Process for making (S)-Pregabalin |
| EP1869007A1 (de) * | 2005-04-14 | 2007-12-26 | Teva Pharmaceutical Industries Ltd | Verfahren zur herstellung von quetiapinfumaraten |
| US20080280977A1 (en) * | 2005-04-26 | 2008-11-13 | Sandor Molnar | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
| KR20090019016A (ko) * | 2005-05-10 | 2009-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 3-카르바모일메틸-5-메틸 헥산산의 광학 분할 |
| MX2007000525A (es) * | 2005-05-10 | 2007-03-28 | Teva Pharma | Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella. |
| WO2006122258A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Method for the preparation of pregabalin and salts thereof |
| WO2006121557A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
| WO2006127933A1 (en) | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Processes for preparing cinacalcet hydrochloride crystal form i |
| WO2007002722A2 (en) * | 2005-06-27 | 2007-01-04 | Sicor, Inc. | Synthesis of anastrozole and purification of one of its intermediate |
| EP1896398A2 (de) * | 2005-06-27 | 2008-03-12 | Sicor Inc. | Verunreinigung des anastrozol-zwischenprodukts und verwendungen dafür |
| JP2008510840A (ja) * | 2005-07-05 | 2008-04-10 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストの精製 |
| CA2619576C (en) * | 2005-08-16 | 2011-12-06 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| US7446220B2 (en) * | 2005-09-19 | 2008-11-04 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
| US20070197529A1 (en) * | 2005-12-01 | 2007-08-23 | Viviana Braude | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
| US7759500B2 (en) * | 2005-12-05 | 2010-07-20 | Teva Pharmaceutical Industries Ltd. | 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride |
| WO2007069264A2 (en) * | 2005-12-15 | 2007-06-21 | Alembic Limited | Reference standards for determining the purity of telithromycin and processes therefor |
| CA2626715A1 (en) * | 2005-12-27 | 2007-07-05 | Teva Pharmaceutical Industries Ltd. | Processes for preparing darifenacin hydrobromide |
| WO2007126886A1 (en) * | 2006-03-27 | 2007-11-08 | Teva Pharmaceuticals Usa, Inc. | Process for preparing memantine hydrochloride substantially free of impurities |
| US20080146675A1 (en) * | 2006-04-05 | 2008-06-19 | Eugenio Castelli | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
| GB0609835D0 (en) * | 2006-05-18 | 2006-06-28 | Pliva Istrazivanje I Razvoj D | Impurities of a pharmaceutical product |
| WO2007139933A2 (en) * | 2006-05-24 | 2007-12-06 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof |
| EP2071032A3 (de) * | 2006-05-31 | 2009-07-08 | Teva Pharmaceutical Industries Ltd | Enzymatische Auflösung für die Herstellung von Pregablin-Zwischenprodukten |
| EP1912931A2 (de) * | 2006-05-31 | 2008-04-23 | Teva Pharmaceutical Industries Ltd. | (s)-prägabalin-nitril-präparat |
| SI2032712T1 (sl) * | 2006-06-29 | 2010-06-30 | Ivax Pharmaceuticals Sro | Regulacija proizvodnje kislinskega metabolita |
| US20120142919A1 (en) * | 2006-08-02 | 2012-06-07 | Medichem, S.A. | Method for synthesizing lamotrigine |
| EP2054396A1 (de) * | 2006-08-14 | 2009-05-06 | Lonza Ag | Verfahren zur herstellung von lamotrigin |
| WO2008106179A1 (en) * | 2007-02-26 | 2008-09-04 | Teva Pharmaceutical Industries Ltd. | Intermediates and processes for the synthesis of ramelteon |
| KR101036536B1 (ko) * | 2007-03-22 | 2011-05-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | (ｓ)-(+)-3-(아미노메틸)-5-메틸 헥산산의 합성 |
| EP2024506A1 (de) * | 2007-04-11 | 2009-02-18 | Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság | Verfahren zur reduzierung des verunreinigungslevels bei der myophenolsäure-fermentierung |
| EP2069320A2 (de) * | 2007-05-31 | 2009-06-17 | Teva Pharmaceutical Industries Ltd. | Verfahren zur synthese von ramelteon und seinen zwischenprodukten |
| US20090137842A1 (en) * | 2007-10-03 | 2009-05-28 | Vollerner Yuri | Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof |
| US8067423B2 (en) * | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
| WO2009056993A2 (en) * | 2007-11-01 | 2009-05-07 | Teva Pharmaceutical Industries Ltd. | A process for the synthesis of ramelteon and its intermediates |
| US8486927B2 (en) * | 2007-11-09 | 2013-07-16 | Thar Pharmaceuticals | Crystalline forms of lamotrigine |
| EP2252574A1 (de) * | 2008-03-06 | 2010-11-24 | Teva Pharmaceutical Industries Ltd. | Verfahren zur herstellung von dimer-unreinheitsfreiem o-desmethylvenlafaxin |
| EP2297090A1 (de) * | 2008-06-23 | 2011-03-23 | Teva Pharmaceutical Industries Ltd. | Stereoselektive enzymatische synthese von (s)- bzw. (r)-iso-butyl-glutarsäure |
| WO2010045565A1 (en) * | 2008-10-16 | 2010-04-22 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of ramelteon and its intermediates |
| CA2795023A1 (en) * | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
| WO2012034065A1 (en) | 2010-09-09 | 2012-03-15 | Teva Pharmaceutical Industries Ltd. | Aliskiren intermediates and a process for analyzing the purity of aliskiren |
| CN102766104A (zh) * | 2012-08-20 | 2012-11-07 | 三金集团湖南三金制药有限责任公司 | 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法 |
| WO2015092819A2 (en) | 2013-12-21 | 2015-06-25 | Nektar Therapeutics (India) Pvt. Ltd. | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine |
| CN110467560A (zh) | 2018-05-09 | 2019-11-19 | 深圳微芯生物科技股份有限公司 | 一种苯基氨基丙酸钠衍生物、其制备方法和应用 |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| CN113156009B (zh) * | 2021-04-20 | 2023-12-22 | 三金集团湖南三金制药有限责任公司 | 高效液相色谱分析拉莫三嗪的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5625169A (en) | 1979-06-01 | 1981-03-10 | Wellcome Found | Triazine derivative |
| EP0021120B1 (de) | 1979-06-01 | 1983-04-06 | The Wellcome Foundation Limited | 3,5-Diamino-1,2,4-triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische Zusammensetzungen sie enthaltend |
| GB8613183D0 (en) | 1986-05-30 | 1986-07-02 | Wellcome Found | Triazine salt |
| GB9426448D0 (en) * | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
| RU2145602C1 (ru) * | 1994-12-30 | 2000-02-20 | Де Вэллкам Фаундейшн Лимитед | Способы получения ламотриджина, промежуточные соединения и способ получения фармацевтической композиции |
| GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
-
1998
- 1998-06-10 GB GBGB9812413.4A patent/GB9812413D0/en not_active Ceased
-
1999
- 1999-02-24 EA EA199900159A patent/EA000666B1/ru not_active IP Right Cessation
- 1999-02-25 SG SG9901252A patent/SG85628A1/en unknown
- 1999-03-09 HR HR990074A patent/HRP990074A2/hr not_active Application Discontinuation
- 1999-03-09 KR KR1019990007632A patent/KR100322354B1/ko active IP Right Review Request
- 1999-03-10 ES ES99200695T patent/ES2178342T3/es not_active Expired - Lifetime
- 1999-03-10 PL PL99331870A patent/PL331870A1/xx not_active Application Discontinuation
- 1999-03-10 BR BR9900984-6A patent/BR9900984A/pt not_active IP Right Cessation
- 1999-03-10 DK DK99200695T patent/DK0963980T3/da active
- 1999-03-10 DE DE69901656T patent/DE69901656T2/de not_active Expired - Fee Related
- 1999-03-10 ZA ZA9901951A patent/ZA991951B/xx unknown
- 1999-03-10 EP EP01203376A patent/EP1170588A1/de not_active Withdrawn
- 1999-03-10 EP EP99200695A patent/EP0963980B1/de not_active Expired - Lifetime
- 1999-03-10 PT PT99200695T patent/PT963980E/pt unknown
- 1999-03-10 TR TR1999/00520A patent/TR199900520A2/xx unknown
- 1999-03-10 JP JP11063792A patent/JP2989189B1/ja not_active Expired - Fee Related
- 1999-03-10 AR ARP990101018A patent/AR014074A1/es not_active Application Discontinuation
- 1999-03-10 HU HU9900592A patent/HUP9900592A3/hu unknown
- 1999-03-10 CA CA002265194A patent/CA2265194C/en not_active Expired - Fee Related
- 1999-03-10 NO NO991151A patent/NO991151L/no unknown
- 1999-03-10 ID IDP990201D patent/ID22957A/id unknown
- 1999-03-10 SI SI9930088T patent/SI0963980T1/xx unknown
- 1999-03-10 MA MA25489A patent/MA24777A1/fr unknown
- 1999-03-10 US US09/265,670 patent/US6333198B1/en not_active Expired - Fee Related
- 1999-03-10 AP APAP/P/1999/001481A patent/AP9901481A0/en unknown
- 1999-03-10 NZ NZ334590A patent/NZ334590A/xx unknown
- 1999-03-10 AT AT99200695T patent/ATE218552T1/de not_active IP Right Cessation
- 1999-03-10 CN CN99103445A patent/CN1238454A/zh active Pending
- 1999-03-10 PE PE1999000190A patent/PE20000332A1/es not_active Application Discontinuation
- 1999-03-10 AP APAP/P/2001/002286A patent/AP0102286A0/en unknown
- 1999-03-10 AU AU20319/99A patent/AU2031999A/en not_active Abandoned
- 1999-03-10 YU YU12399A patent/YU12399A/sh unknown
-
2000
- 2000-01-17 UY UY25946A patent/UY25946A1/es unknown
- 2000-07-25 CN CN00122208A patent/CN1306210A/zh active Pending
-
2001
- 2001-09-06 AP AP2001002286A patent/AP2001002286A0/xx unknown
-
2003
- 2003-06-17 NO NO20032753A patent/NO20032753D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP990074A2 (en) | Compound and its use | |
| EP2089391B1 (de) | Sonde für die bruton-tyrosinkinase-aktivität und verfahren zu ihrer verwendung | |
| CN101939299B (zh) | 油菜素类固醇信号传导的抑制剂 | |
| Bretnall et al. | Metformin hydrochloride | |
| Schwan et al. | Fluorine‐Containing 6, 7‐Dialkoxybiaryl‐Based Inhibitors for Phosphodiesterase 10 A: Synthesis and in vitro Evaluation of Inhibitory Potency, Selectivity, and Metabolism | |
| Alwera et al. | Liquid chromatographic enantioseparation of three beta‐adrenolytics using new derivatizing reagents synthesized from (S)‐ketoprofen and confirmation of configuration of diastereomers | |
| PL162960B1 (pl) | Sposób wytwarzania nowych pochodnych aminofenyloamidyny PL PL PL PL PL PL PL PL | |
| Van Boven et al. | HPLC analysis of diuron and metabolites in blood and urine | |
| Nielsen et al. | Determination of quinidine, dihydroquinidine,(3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography | |
| JP4550279B2 (ja) | レボシメンダンバッチの分析に用いるための対照化合物 | |
| Zhao et al. | Identification, synthesis and characterization of avanafil process impurities and determination by UPLC | |
| Tkalec et al. | Contaminants of emerging concern in urine: a review of analytical methods for determining diisocyanates, benzotriazoles, benzothiazoles, 4-methylbenzylidene camphor, isothiazolinones, fragrances, and non-phthalate plasticizers | |
| Staffeldt et al. | Determination of S-carboxymethyl-l-cysteine and some of its metabolites in urine and serum by high-performance liquid chromatography using fluorescent pre-column labelling | |
| MXPA99002202A (en) | Computeros marcadores y su su | |
| Zhang et al. | Sensitive determination of aliphatic amines by high‐performance liquid chromatography with a new fluorogenic probe 3‐(4‐fluorinebenzoyl)‐2‐quinoline carboxaldehyde | |
| Van Gennip et al. | Urinary excretion of 3-methylxanthine and related compounds in children | |
| Campagna et al. | 2-Aryl-2, 5-dihydropyridazino [4, 3-b] lindol-3 (3H)-ones: novel rigid planar benzodiazepine receptor ligands | |
| Elfarra et al. | Substituent effects on the bioactivation of 2-(N-hydroxyacetamido) fluorenes by N-arylhydroxamic acid N, O-acyltransferase | |
| Huang et al. | Identification, isolation, characterization and ultra-performance liquid chromatography quantification of potential genotoxic impurities in linagliptin | |
| Mörck et al. | Covalent binding of PCB metabolites to lipids: route of formation and characterization | |
| Nageswara Rao et al. | Separation, characterization, and quantitation of process-related substances of the anti-hypertensive drug doxazosin mesylate by reversed-phase LC with PDA and ESI-MS as detectors | |
| Waksmundzka-Hajnos et al. | Determination of the lipophilicity of selected isoquinoline alkaloids by RP-TLC | |
| Barili et al. | A method for the synthesis of racemic and optically active 2‐substituted 9‐(2′, 3′‐dihydroxypropyl)‐8‐azahypoxanthines and 8‐azaadenines | |
| CZ82099A3 (cs) | Způsob zjištění čistoty a stálosti vzorku lanotriginu | |
| Chang et al. | Terazosin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20030206 Year of fee payment: 5 |
|
| OBST | Application withdrawn |